Clinical trials: RAS Wild Type
Colorectal Cancer (CRC)
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
This phase II, single-arm clinical study aims to evaluate the efficacy and safety of toripalimab combined with cetuximab and irinotecan as second-line treatment for patients with advanced right-sided colon cancer with wild-type…
- Trial name
- NCT07896681
- Testing
- Toripalimab, Cetuximab, Irinotecan
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study…
- Trial name
- Everest2 (NCT01251536)
- Testing
- Dose escalation of cetuximab, Standard first line treatment with cetuximab + Folfiri
- Where
- 30 sites in Austria, Belgium and 3 more
- Volunteers
- 108 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer Metastatic
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and < 3…
- Trial name
- VISNU-2 (NCT01640444)
- Testing
- FOLFIRI + bevacizumab, FOLFIRI + cetuximab
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Cancer, Liver Metastases
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
The prognosis of patients with metastatic right-sided colon cancer is worse than that of patients with metastatic left-sided cancer.
- Trial name
- NCT04525326
- Testing
- Cetuximab, Bevacizumab, mFOLFOX/FOLFIRI ( Standard Chemotherapy)
- Volunteers
- 584 people
- Sponsor
- Fudan University
Colorectal Cancer
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.Panitumumab given at 9mg/kg. IV over 30-90 minutes every 3 weeks until disease progression.Primary Objective: To determine the safety of…
- Trial name
- NCT01057017
- Testing
- intervention
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Brown University
RAS Wild Type, Stage IV Colorectal Cancer
Glutamine PET Imaging Colorectal Cancer
The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as…
- Conditions
- RAS Wild Type, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT03275974
- Testing
- Carbon C 11 Glutamine, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Colorectal Cancer
MEK and MET Inhibition in Colorectal Cancer
This trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer.
- Trial name
- MErCuRIC1 (NCT02510001)
- Testing
- PF-02341066, PD-0325901, Binimetinib
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- University of Oxford
Metastatic Colorectal Cancer
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
For the first phase of this study (phase I), the purpose will be to find the dose of a new drug, BKM120, that can safely be given in combination with standard dose panitumumab.
- Trial name
- NCT01591421
- Testing
- BKM120, Panitumumab
- Where
- 3 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Canadian Cancer Trials Group
Colorectal Cancer
Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients
The purpose of this study is to determine whether panitumumab in combination with capecitabine/oxaliplatin are effective as first-line treatment in wild-type k-ras, metastatic colorectal cancer patients.
- Trial name
- NCT01215539
- Testing
- panitumumab
- Where
- 12 sites in Greece
- Volunteers
- 78 people
- Sponsor
- Hellenic Cooperative Oncology Group
Rectal Adenocarcinoma, High-Risk Cancer
SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer
To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma…
- Conditions
- Rectal Adenocarcinoma, High-Risk Cancer, MSS
- Trial name
- CRIT (NCT06908031)
- Testing
- Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer Metastatic, Skin Toxicity
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
The aim of this study is to test the role of cycline in the prevention of acne-like skin rash in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.
- Trial name
- SKINUX (NCT01317433)
- Testing
- Doxycycline, Cetuximab
- Where
- 5 sites in France
- Volunteers
- 25 people
- Sponsor
- Institut Cancerologie de l'Ouest
Metastatic Colorectal Cancer (MCRC)
Phase I/II Combination With Irinotecan- Erbitux
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median…
- Trial name
- NCT00594984
- Testing
- Cetuximab, Irinotecan, Brivanib
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab as first line treatment of patients with initially unresectable and previously untreated RAS wild-type metastatic colorectal cancer…
- Trial name
- AVETRIC (NCT04513951)
- Testing
- 5Fluorouracil, L-leucovorin, Irinotecan
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Neoplasms Malignant
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan（group A） compared to third-line regimens selected by researchers（group B） in…
- Trial name
- NCT05278351
- Testing
- Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer, KRAS Wildtype
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful the combination of two drugs, panitumumab and trametinib, are in patients with advanced colorectal cancer with KRAS, NRAS, or…
- Conditions
- Colorectal Cancer, KRAS Wildtype, NRAS Wildtype, BRAF Wildtype
- Trial name
- NCT02399943
- Testing
- Trametinib, Panitumumab
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University Health Network, Toronto
Colo-rectal Cancer, RAS Wild-type
Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model
In this exploratory phase II trial, the possibility of a personalized treatment after resistance to cetuximab will be evaluated.
- Conditions
- Colo-rectal Cancer, RAS Wild-type, UICC III, UICC II + RF
- Trial name
- 2016-003295-46 (NCT03263663)
- Testing
- targeted substance according to the avatar model
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- PD Dr. med. Volker Heinemann
Colorectal Cancer
Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer
The purpose of the study is to evaluate the efficacy and safety of first-line single-agent panitumumab in frail elderly patients with advanced Wild Type K-RAS colorectal cancer
- Trial name
- FRAIL (NCT01126112)
- Testing
- Panitumumab
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Pancreatic Cancer, PDAC
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- RASolute 304 (NCT07252232)
- Testing
- daraxonrasib
- Where
- 86 sites in United States, Canada and 8 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
Colorectal Cancer
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC.
- Trial name
- ARIEL-ENGIC (NCT07094893)
- Testing
- Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11)
- Volunteers
- 280 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver.
- Trial name
- NCT00803647
- Testing
- cetuximab, 5-FU, oxaliplatin
- Where
- 23 sites in United States
- Volunteers
- 20 people
- Sponsor
- NSABP Foundation Inc